ClinicalTrials.gg
CompletedNCT01854229Updated Oct 18, 2023

Prometra Post-Approval Study

An interventional study of Prometra Programmable Intrathecal Infusion Pump in Chronic Pain, Cancer Pain and Intractable Pain, sponsored by Flowonix Medical. Completed at 26 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-10-18.

Sponsored by Flowonix Medical · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Study summary

The Prometra Pump is approved by the FDA for use in the United States. The purpose of this study is to collect long-term safety data on the Prometra Pump.

Read the detailed description

This study is proposed under part of the post-Premarket Approval (PMA) requirements. This study is a prospective, non-randomized, open-label, multicenter study. It will be performed at 10-30 centers in the US and enroll a maximum of 400 subjects. Subjects will be followed for a total of five years.

02

Conditions studied

  • Chronic Pain
  • Cancer Pain
  • Intractable Pain
  • Back Pain

Keywords

  • Morphine
  • Implantable Infusion Pumps
  • Intrathecal Pump
03

In context

Chronic Pain

3,227 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

This study's enrollment of 400 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Flowonix Medical is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient meets at least one of the following:

    • is suffering from malignant pain (i.e., cancer pain)
    • has chronic, non-malignant pain
    • subject was enrolled in PUMP I or PUMP II study and chooses to participate in this Post-Approval study
    • Patient with an existing implantable pump for pain therapy that requires replacement
  2. Patient is at least 22 years of age.
  3. Investigator considers the patient to be able and willing to fulfill all study requirements.
  4. Patient has provided written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Patient meets any of the for use of the Prometra System
  2. Patient has a prior history of granuloma formation, or is receiving treatment for a suspected granuloma.
  3. Patient is pregnant or breast-feeding or is of and not employing effective .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Active comparator
    Prospective pump candidates

    New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump

    Device: Prometra Programmable Intrathecal Infusion Pump

  • Active comparator
    Previous IDE study subjects continuing with the therapy

    Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.

    Device: Prometra Programmable Intrathecal Infusion Pump

Interventions

  • DevicePrometra Programmable Intrathecal Infusion Pump

    There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.

    Also known as: Flowonix pump

06

What researchers measure

Primary outcomes

  1. Rate of granuloma formation

    The primary hypothesis is that the 5-year rate of patients with granuloma formation will be noninferior to that in the literature. The literature rate was found to be approximately 3% and the noninferiority margin will be three percentage points.

    Time frame: Five years

Secondary outcomes

  1. Pump failure

    Tabulation of pump failures, including time to occurrence and type

    Time frame: Five years

  2. Pump battery life

    Tabulation of occurences of premature pump battery depletions

    Time frame: Five years

Other outcomes

  1. Device-related adverse events

    Tabulation of device-related adverse events

    Time frame: Five years

  2. Device-related serious adverse events

    Tabulation of device-related serious adverse events

    Time frame: Five years

  3. Rate of granuloma formation by race and ethnicity

    The effect of race and ethnicity on granuloma formation

    Time frame: Five years

  4. Granuloma formation by drug type

    The effect of alternative drugs on granuloma formation

    Time frame: Five years

07

Study locations

26 sites
  • Perlman Clinic
    La Jolla, California 92037, United States
  • Pacific Pain Physicians
    Santa Barbara, California 93105, United States
  • Evolve Restorative Center
    Santa Barbara, California 95403, United States
  • Summit Pain Alliance
    Santa Rosa, California 95401, United States
  • BioHealth Pain Management
    Torrance, California 90260, United States
  • Interventional Pain Management
    Daytona Beach, Florida 32174, United States
  • Florida Institute of Medical Research
    Jacksonville, Florida 32257, United States
  • Palm Beach Pain Management
    Lake Worth, Florida 33462, United States
  • Pain Institute of Tampa
    Tampa, Florida 33603, United States
  • Global Scientific Innovations
    Evansville, Indiana 47714, United States
  • Summit Pain Management
    Fort Wayne, Indiana 46802, United States
  • Summit Research Institute
    Fort Wayne, Indiana 46825, United States
  • Interventional Pain Management Specialists
    Overland Park, Kansas 66209, United States
  • Bluegrass Pain Consultants
    Louisville, Kentucky 40202, United States
  • Kentuckiana Pain Specialists
    Louisville, Kentucky 40241, United States
  • Neuroscience and Pain Institute
    Covington, Louisiana 70433, United States
  • Integrated Pain and Neuroscience
    New Orleans, Louisiana 70115, United States
  • Jackson Anesthesia Pain Center
    Jackson, Mississippi 39202, United States
  • Triumph Medical
    Asheville, North Carolina 28803, United States
  • Integrated Pain Solutions
    Columbus, Ohio 43219-1531, United States
  • Pain Management Institute
    Wooster, Ohio 44691, United States
  • Neurospine Institute
    Eugene, Oregon 97401, United States
  • Pain Care of Oregon
    Medford, Oregon 97504, United States
  • Fox Chase Pain Management Associates
    Trevose, Pennsylvania 19053, United States
  • Space City Pain Specialists
    Webster, Texas 77598, United States
  • Nexus Pain Care
    Provo, Utah 84604, United States
08

References and documents

Publications

  • Rauck R, Deer T, Rosen S, Padda G, Barsa J, Dunbar E, Dwarakanath G. Long-term follow-up of a novel implantable programmable infusion pump. Neuromodulation. 2013 Mar-Apr;16(2):163-7. doi: 10.1111/j.1525-1403.2012.00515.x. Epub 2012 Oct 11. PubMed 23057877 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01854229
Lead sponsor
Flowonix Medical
Responsible party
Sponsor
First posted
May 15, 2013
Start date
Jun 20, 2013
Primary completion
Mar 15, 2023
Completion
Mar 15, 2023
Last update
Oct 18, 2023

Study contacts

Cory Brantley
study director · Flowonix Medical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion